8/15/2022 6:52:44 AM
NRx Pharma Q2 Net Loss $7.0 Mln Vs Loss Of $0.1 Mln Last Year
7/13/2022 7:17:35 AM
NRx Pharma Appoints Stephen Willard As CEO
7/1/2022 7:36:29 AM
NRx : FDA Declines Emergency Use Authorization For ZYESAMI For Subgroup Of Patients With Critical COVID-19
6/10/2022 11:55:19 PM
NRx Pharma Says FDA Denies Breakthrough Therapy Designation Request For ZYESAMI
6/7/2022 9:12:31 PM
NRx Pharma Appoints Seth Van Voorhees As CFO And Treasurer Effective June 13
5/26/2022 12:07:45 AM
NRx Pharmaceuticals Announces DSMB Update On NIH Study Of ZYESAMI In Critical COVID-19
5/16/2022 7:32:27 AM
NRx Pharma Q1 Net Loss $13.4 Mln Or $0.21/shr Vs Loss Of $25.5 Mln, Or $0.71/shr Prior Year
5/12/2022 8:18:31 AM
NRx Announces Enrollment Of First Patient In Phase II Study Of Bipolar Depression With Sub-Acute Suicidality
4/21/2022 8:50:02 AM
NRx Files Breakthrough Therapy Designation Request For ZYESAMI In Subgroup Of Patients With Critical COVID-19
3/31/2022 8:25:47 AM
NRx:I-SPY COVID Trial Shows No Benefit With Addition Of ZYESAMI When Given By Mouth Inhalation In Ill COVID-19 Patients
3/31/2022 8:21:49 AM
NRx Pharma FY Net Loss $93.1 Mln Or $1.98/shr Vs. Loss Of $51.8 Mln Or $1.51/shr Prior Year